NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









TJ Biopharma

TJ Biopharma

Private
HangzhouHealthcare & Life Scienceshttps://tjbio.com/

Last Round

Series C

Extension

Sep 30, 2025

Total Funding Raised

$116M

Company Overview

TJ Biopharma is a biotechnology company that develops, manufactures, and commercializes innovative biologics for autoimmune diseases, immuno-oncology, and metabolic disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Clean Manufacturing

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Data as a Service

AI Layer

Non-AI

Keywords

biologicsmonoclonal antibodybispecific antibodyCDMOcontract manufacturingbiotechdrug discoveryimmuno-oncologyautoimmune diseaseGMP manufacturingbiopharmametabolic disordersdrug licensingantibody engineering

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

TJ Biopharma Comps

Public and private peers based on sector, stage, and business model.

TJ Biopharma comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

TJ Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 30, 2025
Series C ExtensionFeb 7, 2024
Series BJul 16, 2022
Series ASep 15, 2020

TJ Biopharma Investors

Notable investors and investment history

TJ Biopharma investors
InvestorRounds
Oriental Fortune CapitalSeries C Extension
CCIC CapitalSeries C Extension
Hangzhou Industrial & Commercial TrustSeries A, Series B
Viva BiotechSeries A, Series B
Value Partners GroupSeries A, Series B
Yijing CapitalSeries C Extension
Zhejiang Haibang Private Equity Fund Management Co., Ltd.Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 16, 2022

    $46M round with participation from Value Partners Group.

TJ Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

TJ Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about TJ Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Employee Range11
Year Founded2019
Last FundingSep 30, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.